The battle against B Cell High Risk Acute Lymphoblastic Leukemia has been beyond challenging for 12-year-old Nicholas Childers of Savannah. The Hancock Day School seventh-grader has endured multiple medical complications during rigorous treatment since being diagnosed with B-ALL in 2015.
Category: Leukemia
Monoclonal antibody drug superior to chemotherapy for advanced acute lymphoblastic leukemia
A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard chemotherapy for treatment of advanced acute lymphoblastic leukemia . Study findings were published in the March 1 online issue of the New England Journal of Medicine .
Researchers create novel model that reveals cellular, molecular events driving leukemia progression
Mount Sinai researchers have created a novel model that shows the step-by-step progression from normal blood cells to leukemia and its precursor diseases, creating replicas of the stages of the disease to test the efficacy of therapeutic interventions at each stage, according to a study to be published in Cell Stem Cell. This research marked the first time scientists have been able to transplant leukemia from humans to a test tube and then into mice for study, a landmark feat that will allow for valuable research to help find therapies for blood cancer patients in the future.
Why are Canadians over 35 barred from signing up to donate bone marrow?
Bone marrow is the body’s production plant for blood, and donated marrow is sometimes the only treatment for patients with leukemia. A few years ago, Yael Heffer wanted to get on the Canadian bone marrow donor list.
Pluristem Therapeutics And New York Blood Center To Collaborate In…
Pluristem Therapeutics And New York Blood Center To Collaborate In Evaluating PLX-R18 As An Adjuvant Therapy To Umbilical Cord Blood Transplantation, Winning $900,000 Funding From BIRD Prior research has suggested that PLX-R18 helps cord blood cells to engraft more rapidly and effectively Grant of $900,000 from Israel-U.S. Binational Industrial Research and Development Foundation to fund the research Constitutes a 3rd potential hematologic indication for PLX-R18 HAIFA, Israel, Dec. 27, 2016 — Pluristem Therapeutics Inc. , a leading developer of placenta-based cell therapy products, today announced that it will collaborate with the New York Blood Center on preclinical studies of its Placental eXpanded -R18 cells to enhance the efficacy of umbilical cord blood transplantation.